Literature DB >> 16935271

Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptor-dependent manner.

Catarina A R V Gomes1, Sandra H Vaz, Joaquim A Ribeiro, Ana M Sebastião.   

Abstract

Both glial cell line-derived neurotrophic factor (GDNF) and adenosine influence dopaminergic function in the striatum. We now evaluated the GDNF effect on dopamine release from rat striatal nerve endings and if this effect of GDNF is modulated by adenosine A(2A) receptors. Dopamine release was evoked twice (S(1) and S(2)); GDNF was added before S(2) and drugs used to modify GDNF actions were present during both stimulation periods. The effect of GDNF was taken as the change in the S(2)/S(1) ratio in the absence and in the presence of GDNF in the same experimental conditions. GDNF (3-30 ng/ml) increased dopamine release from K(+) (20 mM, 2 min) stimulated synaptosomes and electrically (2 Hz, 2 min) stimulated striatal slices, an effect dependent upon tonic adenosine A(2A) receptor activation, since it was blocked by the A(2A) receptor antagonist, SCH 58261 (50 nM). Activation of A(2A) receptors with CGS 21680 (10 nM) potentiated the effect of GDNF in synaptosomes. CGS 21680 also potentiated the effect of GDNF in striatal slices, providing that GABAergic transmission was inhibited; if not, the action of GDNF was attenuated by CGS 21680. Blockade of GABAergic transmission per se increased dopamine release, but attenuated the effect of GDNF upon dopamine release in slices. The results suggest that GDNF enhances dopamine release by acting presynaptically at the striatum, an action that requires adenosine A(2A) receptor activity. Furthermore, in striatal slices, the action of GDNF as well as its modulation by adenosine A(2A) receptor activation appears to be also under control of GABAergic transmission.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935271     DOI: 10.1016/j.brainres.2006.07.025

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

1.  An analysis of the rewarding and aversive associative properties of nicotine in the neonatal quinpirole model: Effects on glial cell line-derived neurotrophic factor (GDNF).

Authors:  Russell W Brown; Seth L Kirby; Adam R Denton; John M Dose; Elizabeth D Cummins; Wesley Drew Gill; Katherine C Burgess
Journal:  Schizophr Res       Date:  2017-03-14       Impact factor: 4.939

2.  Dysregulation of brain adenosine is detrimental to the expression of conditioned freezing but not general Pavlovian learning.

Authors:  Philipp Singer; Chuchu Zhang; Detlev Boison; Benjamin K Yee
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

3.  Constitutive activity of the A2A adenosine receptor and compartmentalised cyclic AMP signalling fine-tune noradrenaline release.

Authors:  Edin Ibrisimovic; Helmut Drobny; Qiong Yang; Thomas Höfer; Stefan Boehm; Christian Nanoff; Klaus Schicker
Journal:  Purinergic Signal       Date:  2012-04-05       Impact factor: 3.765

Review 4.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

5.  GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors.

Authors:  Catarina A R V Gomes; Patrícia F Simões; Paula M Canas; César Quiroz; Ana M Sebastião; Sergi Ferré; Rodrigo A Cunha; Joaquim A Ribeiro
Journal:  J Neurochem       Date:  2009-01-29       Impact factor: 5.372

6.  Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.

Authors:  Tobias Gyárfás; Juha Knuuttila; Päivi Lindholm; Tomi Rantamäki; Eero Castrén
Journal:  Cell Mol Neurobiol       Date:  2009-09-24       Impact factor: 5.046

7.  Tuning and fine-tuning of synapses with adenosine.

Authors:  A M Sebastião; J A Ribeiro
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

8.  Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anna R Carta; Anil Kachroo; Nicoletta Schintu; Kui Xu; Michael A Schwarzschild; Jadwiga Wardas; Micaela Morelli
Journal:  J Neurochem       Date:  2009-10-08       Impact factor: 5.372

Review 9.  Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection.

Authors:  Ana M Sebastião; Joaquim A Ribeiro
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

10.  Functional interaction between pre-synaptic α6β2-containing nicotinic and adenosine A2A receptors in the control of dopamine release in the rat striatum.

Authors:  P Garção; E C Szabó; S Wopereis; A A Castro; Â R Tomé; R D Prediger; R A Cunha; P Agostinho; A Köfalvi
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.